The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming.
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Manuela Terranova Barberio
No Relationships to Disclose
 
Nela Pawlowska
Employment - Allergan (I)
Travel, Accommodations, Expenses - Allergan (I)
 
Mark Moasser
No Relationships to Disclose
 
Amy Jo Chien
Research Funding - Merck (Inst)
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Galena Biopharma (Inst); Genentech (Inst); Lilly (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Hope S. Rugo
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
Speakers' Bureau - Genomic Health
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech
 
Kamran Abri
No Relationships to Disclose
 
Armand Harb
No Relationships to Disclose
 
Travis Deal
No Relationships to Disclose
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Scott Thomas
No Relationships to Disclose